Anti-TNF agents in Crohn’s disease

Bibliography

• FIOCCHI C: Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology (1998) 115:182–205.
   PubMed Web of Science ®Google Scholar
• •Detailed review of the current hypotheses on the aetiology of Crohn's disease.
   Google Scholar
• VAN DEVENTER SJH, ELSON CO, FEDORAK RN: Multipledoses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology (1997) 113:383–389.
   PubMed Web of Science ®Google Scholar
• SANDS BE, BANK S, SHINSKY CA et al: Preliminaryevaluation of safety and activity of recombinant interleukin 11 in patients with active Crohn's disease. Gastroenterology (1999) 117:58–64.
   PubMed Web of Science ®Google Scholar
• NEURATH MF, FUSS I, PASPARAKIS M et al.: Predominantpathogenic role of tumor necrosis factor in experi-mental colitis in mice. Eur. J. Immunol. (1997) 27:1743–1750.
   PubMed Web of Science ®Google Scholar
• •This paper provides firm evidence of the importance of TNF in an experimental model of IBD colitis.
   Google Scholar
• MURCH SH, BRAEGER CP, WALKER-SMITH JA et al: Location of tumor necrosis factor alpha by immunehistochemistry in chronic inflammatory bowel disease. Gut (1993) 34:1705–1709.
   PubMed Web of Science ®Google Scholar
• MURCH SH, LAMKIN VA, SAVAGE MO et al: Serum concentrations of tumor necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut (1991) 32:913–917.
   PubMed Web of Science ®Google Scholar
• AGARWALL BB, KOHR WJ, HASS PE et al.: Human tumor necrosis factor. Production, purification and charac-terization. J. Biol. Chem. (1985) 260:2345–2354.
   PubMed Web of Science ®Google Scholar
• SMITH RA, BAGLIONI C: The active form of tumor necrosis factor is a trimer. J. Biol. Chem. (1987) 262:6951–6954.
   PubMed Web of Science ®Google Scholar
• FLIER JS, UNDERHILL LH: The tumor necrosis factor ligand and receptor families. N Engl. J. Med. (1996) 334:1717–1725.
   PubMed Web of Science ®Google Scholar
• ••Concise review of the molecular biology of TNF and itsimportance in human disease.
   Google Scholar
• KNIGHT DM, TRINTH H, LE J et al: Construction and initial characterization of a mouse-human chimeric anti TNFantibody. Mol Immunol. (1993) 30:1443–1453.
   PubMed Web of Science ®Google Scholar
• •Original paper describing the dicovery of the first clinically relevant monoclonal anti- TNF-antibody.
   Google Scholar
• ISAACS JD, WATTS RA, HAZELMAN BL et al.: Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet (1992) 340:748–752.
   PubMed Web of Science ®Google Scholar
• SIEGEL SA, SHEALY DJ, NAKADA MT et al.: Themouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine (1995) 7:15–25.
   PubMed Web of Science ®Google Scholar
• SCALLON BJ, MOORE MA, TRINH H et al: Chimeric anti-TNF-a monoclonal antibody binds recombinant transmembrane TNF-a and activates immune effector functions. Cytokine (1995) 7:251–259.
   PubMed Web of Science ®Google Scholar
• PLEVY SE, LANDERS CJ, PREHN J et al.: A role for TNFaand mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J. Immunol. (1997) 159:6367–6282.
   Google Scholar
• •This paper provides experimental evidence that TNF-antibodies interacts with TNF to ameliorate Crohn's disease.
   Google Scholar
• WAGNER C, MACE K, DEWOODY K et al.: Infliximab treatment benefits correlate with pharmacodynamic parameters in Crohn's disease patients. Digestion (1998) 59:124–125.
   Google Scholar
• REMICADEO (INFLIXIMAB). Product monograph (1999).
   Google Scholar
• MOHLER KM, TORRANCE DS, SMITH CA et al: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as TNF carriers and TNF antagonists. J. Immunol. (1993) 151:1548–1561.
   PubMed Web of Science ®Google Scholar
• JACOBS CA, BECKMANN MP, MOHLER KM: Pharmacoki-netic parameters and biodistribution of soluble cytokine receptors. Int. Rev. Exp. PathoL (1993) 34B:123–135.
   Google Scholar
• DERX B, TAMINIAU J, RADEMA S et al: Tumor-necrosis-factor antibody treatment in Crohn's disease. Lancet (1993) 342:173–174.
   Web of Science ®Google Scholar
• VAN DULLEMEN HM, VAN DEVENTER SJH, HOMMES DW et al: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 109:129–135.
   PubMed Web of Science ®Google Scholar
• ••First report on the treatment of Crohn's disease withanti-TNF antibodies in a limited number of patients.
   Google Scholar
• MCCABE RP, WOODY J, VAN DEVENTER S et al: A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease. Gastroenterology (1996) 110:A962. (Abstract).
   Google Scholar
• TARGAN SR, HANAUER SB, VAN DEVENTER SJH et al.: A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl. J. Med. (1997) 337:1092–1035.
   Google Scholar
• •Paper describing the results of the largest multi-centre trial to date focusing on the short term treatment of refractory Crohn's disease with infliximab.
   Google Scholar
• D'HAENS GD, VAN DEVENTER SJH, VAN HOGEZAND R et al.: Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease. Gastroenterology (1999) 116:1029–1034.
   Google Scholar
• •This paper shows that clinical improvement with infliximab is reflected in amelioration of endoscopic and histological scores in a proportion of patients enrolled in the multi-cenrer clincal trial (see [221)
   Google Scholar
• BAERT FJ, D'HAENS GD, PEETERS M et al. Tumor necrosis factor a antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileoco-litis. Gastroenterology (1999) 116:22–28.
   Google Scholar
• RUTGEERTS P, D'HAENS GD, TARGAN S et al: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 117:761–769.
   PubMed Web of Science ®Google Scholar
• PRESENT D, RUTGEERTS P, TARGAN S et al: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl. J. Med. (1999) 340:1398–1405.
   PubMed Web of Science ®Google Scholar
• •Paper demonstrating the effectiveness of infiliximab in a large number of patients with fistulising Crohn's disease
   Google Scholar
• STACK WA, MANN SD, ROY AJ et al.: Randomised controlled trial of CDP571 antibody tot tumor necrosis factor-a in Crohn's disease. Lancet (1997) 349:521–524.
   PubMed Web of Science ®Google Scholar
• BAUDITZ J, HAEMLING J, ORTNER M et al: Treatment with tumor necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut (1997) 40:470–474.
   PubMed Web of Science ®Google Scholar
• KANE SV, EHRENPREIS ED, COHEN LB, HANAUER SB, COHEN RD: Therapeutic efficacy of thalidomide for patients with refractory Crohn's disease. Gastroenter-ology(1999) 116:A745 (Abstract).
   Google Scholar
• HANAUER SB, RUTGEERTS P, D'HAENS G et al. Delayed hypersensitivity to inflximab (Remicade®) re-infusion after a 2–4 year interval without treatment. Gastroenter-ology (1999) 116:A731. (Abstract).
   Google Scholar
• GREENSTEIN AJ, MULLIN GE, STRAUCHEN JA et al: Lymphoma in inflammatory bowel disease. Cancer (1992) 69:1119–1121.
   PubMed Web of Science ®Google Scholar
• MAINI RN, BREEVELD FC, KALDEN JR et al: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1998) 41:1552–1563.
   PubMed Web of Science ®Google Scholar
• •Paper reporting on the additional benefit of combining methotrexate with infilximab in RA patients, which has led to current interest in combining immunesuppressive agents with infliximab.
   Google Scholar